Healthcare provider profile · identity verified

Robert A Gerber, MD

Internal Medicine · GRAYSLAKE, IL · NPI 1568618296

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	466	136
Amlodipine Besylate	Amlodipine Besylate	204	62
Levothyroxine Sodium	Levothyroxine Sodium	188	52
Lisinopril	Lisinopril	174	51
Omeprazole	Omeprazole	142	51
Valsartan	Valsartan	138	41
Metformin Hcl Er	Metformin Hcl	129	37
Metoprolol Succinate	Metoprolol Succinate	128	41
Gabapentin	Gabapentin	119	27
Losartan Potassium	Losartan Potassium	117	35
Rosuvastatin Calcium	Rosuvastatin Calcium	114	35
Trazodone Hcl	Trazodone Hcl	101	28
Metformin Hcl	Metformin Hcl	99	29
Escitalopram Oxalate	Escitalopram Oxalate	84	21
Pantoprazole Sodium	Pantoprazole Sodium	81	28
Simvastatin	Simvastatin	81	21
Albuterol Sulfate Hfa	Albuterol Sulfate	80	27
Fluticasone Propionate	Fluticasone Propionate	78	27
Pravastatin Sodium	Pravastatin Sodium	69	22
Tamsulosin Hcl	Tamsulosin Hcl	69	20
Jardiance	Empagliflozin	68	11
Metoprolol Tartrate	Metoprolol Tartrate	68	20
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	60	18
Hydrochlorothiazide	Hydrochlorothiazide	57	19
Xarelto	Rivaroxaban	56	suppressed
Sertraline Hcl	Sertraline Hcl	51	11
Eliquis	Apixaban	49	12
Furosemide	Furosemide	49	16
Allopurinol	Allopurinol	48	13
Meloxicam	Meloxicam	46	19
Lorazepam	Lorazepam	45	11
Trulicity	Dulaglutide	44	suppressed
Carvedilol	Carvedilol	38	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	38	11
Rybelsus	Semaglutide	37	suppressed
Pregabalin	Pregabalin	36	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	36	suppressed
Ozempic	Semaglutide	34	suppressed
Ezetimibe	Ezetimibe	33	suppressed
Mounjaro	Tirzepatide	31	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	31	suppressed
Duloxetine Hcl	Duloxetine Hcl	30	suppressed
Irbesartan	Irbesartan	29	suppressed
Synthroid	Levothyroxine Sodium	27	suppressed
Alendronate Sodium	Alendronate Sodium	26	suppressed
Linzess	Linaclotide	26	suppressed
Montelukast Sodium	Montelukast Sodium	25	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	24	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	23	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	21	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	21	suppressed
Potassium Chloride	Potassium Chloride	21	suppressed
Januvia	Sitagliptin Phosphate	20	suppressed
Finasteride	Finasteride	19	suppressed
Hydrocortisone	Hydrocortisone	19	suppressed
Alprazolam	Alprazolam	18	suppressed
Celecoxib	Celecoxib	18	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	18	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	17	suppressed
Atenolol	Atenolol	17	suppressed
Chlorthalidone	Chlorthalidone	17	suppressed
Clonazepam	Clonazepam	17	suppressed
Clopidogrel	Clopidogrel Bisulfate	17	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	17	suppressed
Benazepril Hcl	Benazepril Hcl	16	suppressed
Glipizide	Glipizide	14	suppressed
Ondansetron Odt	Ondansetron	14	suppressed
Azelastine Hcl	Azelastine Hcl	13	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	13	suppressed
Mirtazapine	Mirtazapine	13	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	13	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	12	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	12	suppressed
Warfarin Sodium	Warfarin Sodium	12	suppressed
Diclofenac Sodium	Diclofenac Sodium	11	suppressed
Estradiol	Estradiol	11	suppressed
Glipizide Er	Glipizide	11	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	11	suppressed
Oxycodone Hcl	Oxycodone Hcl	11	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error